AP Altria‘s $ 1.8 billion investment in the cannabis producer Cronos is mutually beneficial, a Cowen analyst says. Cronos has a focus on rare cannabinoids, which has greater potential than just focusing on the two most known cannabinoids, Azer added. Cronos can leverage Altria’s expertise to focus on ingredient composition without reliance on a massive cultivation […]
